Pathology Scientific Lecture Series 2019-2020

Monday, October 28, 2019  1:15 pm

Development and Direction of Oncologic Pathology
What’s new in lung cancer diagnosis?

Zhaolin Xu MD, FRCPC, FCAP
Professor, Dept. of Pathology, Dalhousie University, Halifax, NS
Pulmonary Pathologist and Cytopathologist, QEII Health Sciences Centre, Halifax, NS
Senior Scientist, Beatrice Hunter Cancer Research Institute, Halifax, NS

Dr. Zhaolin Xu is a pulmonary pathologist and cytopathologist certified by both the Royal College of Physicians and Surgeons of Canada and the American Board of Pathology. He is also a professor in the Department of Pathology, Dalhousie University. Dr. Xu is not only an expert in pulmonary pathology and cytopathology, but also a cancer researcher who holds the position of Senior Scientist in the Beatrice Hunter Cancer Research Institute. Dr. Xu established the QE II Lung Tumor Bank in 2005, and he is the Director of the tumor bank which is certified by the Canadian Tissue Repository Network (CTRNet). Dr. Xu is also the driving force to establish and implement multiplexed molecular profiling and biomarker testing for lung cancer in a clinical setting in Nova Scotia and Atlantic Canada. He is a Panel Member in the Lung National Cancer Pathology and Staging Multidisciplinary Expert Panel, and Network Member in the Pan-Canadian Lung Cancer Screening Network, CPAC. He is the Cancer Protocol Review Panel Member for pulmonary and mediastinum tumors in the College of American Pathologists. He holds memberships in the Correlative Science and Tumor Biology Committee and Lung Cancer Subcommittee in the Canadian Cancer Trial Group. He is also the Chair of the Research Committee, member of Medical Advisory Committee and the Board of Directors of Lung Cancer Canada. In addition Dr. Xu sits in the National Lung Cancer Advisory Committees for many pharmaceutical companies.

FOR MORE INFORMATION: pathologysec.med@mcgill.ca

Sponsored by

abbvie

McGill